Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3639 Tumor uptake on 18FDOPA PET/CT is a strong prognostic factor in patients with metastatic small intestine neuroendocrine tumors (siNETs) – A GTE study

Introduction: 18FDOPA PET/CT has high diagnostic performances for siNETs. Its prognostic role is unknown.

Conference:

Presenting Author: de Mestier L

Authors: de Rycke O, Imperiale A, Perrier M, Bando-Delaunay A, Mennetrey C,

Keywords: FDOPA PET/CT, prognosis, small intestine NETs,

#309 The Utility of Alpha Internexin as a Predictive Tissue Biomarker for Proliferation in Gastrointestinal and Pancreatic Neuroendocrine Tumors

Introduction: GEP-NETs are increasing but Ki-67 and CgA provide limited information regarding malignancy. A key unmet need is alternative biomarkers to assess the likelihood of local invasion or metastasis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Schimmack S, Lawrence B, Svejda B, Fischer L, Schmitz-Winnenthal H,

Keywords: alpha-internexin, biomarker, GEP-NET, INA, Ki-67, malignancy, metastasis, neuroendocrine tumor, PCR,

#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection

Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Giandomenico V

Authors: Cui T, Elgue G, Li S, Hurtig M, Veronesi G,

Keywords: Small intestine neuroendocrine tumors, novel diagnostic biomarker, PNMA2, auto-antibodies as serum biomarker.,